Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereof
US10675349B2 · kind B2 · utility
2Cited by
20References
25Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 6, 2015 |
| Grant date | Jun 9, 2020 |
| Priority date | — |
| Expiry date | Oct 14, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/01
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor CCR4. This antibody is derived from CCR4-IgG1 and recognizes the same epitope. This antibody contains either an IgG4 or a stabilized IgG4 in order to improve binding efficiency and reduce in vivo Fab arm exchange. Binding of the antibodies disclosed herein to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.